Klin Farmakol Farm. 2004;18(3):181-182

Nefrotoxicita indometacinu u novorozenců

Zdeněk Doležel, Dan Wechsler, Lia Elstnerová
II. dětská klinika LF MU a FN Brno

Keywords: indomethacin, acute renal failure, newborn.

Published: December 31, 2004  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Doležel Z, Wechsler D, Elstnerová L. Nefrotoxicita indometacinu u novorozenců. Klin Farmakol Farm. 2004;18(3):181-182.

V klinické studii byl u nedonošených novorozenců hodnocen vztah mezi podávaným indometacinem a rozvojem akutního selhání ledvin. Důvodem k intravenóznímu podávání indometacinu byla snaha o uzavření průchodného ductus arteriosus. U hodnoceného souboru byla incidence akutního poškození ledvin 24 %, ale tento stav byl přechodný. Přesto je třeba velké opatrnosti v podávání indometacinu nedonošeným novorozencům, neboť za přispění některých dalších faktorů může být renální alterace závažnější.

INDOMETHACIN AND RENAL IMPAIRMENT IN NEONATES

The aim of this study was to determine the incidence of renal impairment in infants treated with indomethacin in a single center, to determine whether there is evidence of renal impairment on day 30, and to identify risk factors for renal impairment. Of infants who were less than 30 weeks compled gestation, 24 % had acute but reversible acute renal failure following indomethacin administration.

Download citation

References

  1. Akima S, Kent A, Reynolds GJ, Gallagher M, Falk MC. Indomethacin and renal impairment in neonates. Pediatr Nephrol 2004; 19: 490-493. Go to original source... Go to PubMed...
  2. Edwards AD, Wyatt JS, Richardson C, Potter A, Cope M, Delpy DT, Reynolds EDR. Effects of indomethacin on cerebral hemodynamics in very preterm infants. Lancet 1990; 335: 1491-1495. Go to original source... Go to PubMed...
  3. Narayan M, Cooper B, Weiss H, Clyman RI. Prophylactic indomethacin: factors determining permanent ductus closure. J Pediatr 2000; 136: 330-337. Go to original source... Go to PubMed...
  4. Schmidt B, Davis P, Moddemann D, Ohlsson A, Roberts RS, Saigal S, Solimano A, Vincer M, Wright LL. Long-term effects on indomethacin prophylaxis in exremly-low-birth-weight infants. N Engl J Med 2001; 344: 1966-1972. Go to original source... Go to PubMed...
  5. Van Overmeire B, Smets K, Lecoutere D, Van de Broek H, Weyler J, Degroote K, Langhendries JP. A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus 2000; N Engl J Med 343: 674-681. Go to original source... Go to PubMed...
  6. Saarela T, Lanning P, Koivisto M, Paavilainen T. Nephrocalcinosis in full-term infants receiving furosemide treatment for congestive heart failure: a study of the incidence and 2-year follow up 1999; Eur J Pediatr 158: 668-672. Go to original source... Go to PubMed...




Clinical Pharmacology and Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.